Close

Press Releases

Atreca Reports on Tumor-­Fighting Responses in B Cells from Patients with Non-Progressing Metastatic Cancers

December 19, 2017

REDWOOD CITY, Calif. — Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today publication of noteworthy results in preclinical cancer research enabled by Atreca’s Immune Repertoire Capture® (IRC™) technology. As reported in Clinical Immunology (DOI: 10.1016/j.clim.2017.10.002), Atreca scientists, collaborating with researchers at Stanford University and California Pacific Medical Center, demonstrated that patients with non-­progressing, metastatic cancer generate antibodies directed against public tumor antigens (epitopes present in tumors of more than one patient) in a manner having the hallmarks of a typical antigen-­driven humoral immune response. In preclinical in vivo models, certain of these antibodies also induce tumor regression and durable anti-­tumor immunity. The research involved the sequencing and analysis of native antibodies accessed from single B cells in the active, ongoing anti-­tumor immune responses of non-­progressing patients with metastatic melanoma, lung adenocarcinoma, or renal cell carcinoma.

“This published research further confirms our ability to use IRC™ technology to validate B cell responses as a vital window for understanding effective patient immune responses in cancer, including the discovery of patient antibodies serving as the foundation for therapeutic discovery,” commented William H. Robinson, M.D., Ph.D., Atreca board member, Co-­Founder, and Associate Professor of Medicine in the Division of Immunology and Rheumatology of the Department of Medicine at Stanford University, as well as co-­author on the published research. “By measuring key features of the immune response from non-­progressing patients, including patient antibodies’ targeting of antigens expressed across multiple cancer types, we now have important new evidence of the role of B cells in mounting effective immune responses to cancer.”

“We are proud of this seminal work, having discovered key features of patient immune responses to cancer. By examining single patient B cells, Atreca has a unique opportunity to understand productive anti-­tumor responses and develop effective, next-­generation cancer immunotherapies,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-­Founder. “Based on these and other compelling research findings, Atreca is executing on its goals of both identifying the widest range of antibodies targeting public tumor antigens and advancing a robust therapeutic pipeline using that information.”

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-­cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® technology profiles a patient’s immune response at the single-­cell  level  at  very  high  throughput  essentially  without  bias  or  error,  enabling  the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.

Atreca’s technology provides unbiased and virtually error-­free antibody and T cell receptor (TCR) sequences at from single B and T cells of active human immune responses, enabling the identification, generation, and analysis of functional human antibodies and TCRs directly from such responses.

Contacts

Atreca, Inc.
Susan Berland
EVP and Chief Financial Officer
info@atreca.com

Media:
Justin Jackson, 212-213-0006, ext. 327
jjackson@burnsmc.com

Investors:
John Grimaldi, 212-213-0006, ext. 362
jgrimaldi@burnsmc.com